BCL2 and diffuse large B-cell lymphoma: Our data and others have revealed that chronic ibrutinib exposure can reprogram resistant cells to express high levels of BCL2 [139], and therefore venetoclax may have synergistic anti-proliferative activity when combined with ibrutinib for combination therapy in resistant ABC-DLBCL lines and primary tumors [149].